Pozet, Astrid
33  results:
Search for persons X
?
1

Chemotherapy use in end-of-life digestive cancer patients: ..:

Lapeyre-Prost, Alexandra ; Perkins, Geraldine ; Vallee, Marie...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinre.2021.101709.  , 2021
 
?
2

Chemotherapy use in end-of-life digestive cancer patients: ..:

Lapeyre-Prost, Alexandra ; Perkins, Geraldine ; Vallee, Marie...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinre.2021.101709.  , 2021
 
?
3

Chemotherapy use in end-of-life digestive cancer patients: ..:

Lapeyre-Prost, Alexandra ; Perkins, Geraldine ; Vallee, Marie...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinre.2021.101709.  , 2021
 
?
4

Chemotherapy use in end-of-life digestive cancer patients: ..:

Lapeyre-Prost, Alexandra ; Perkins, Geraldine ; Vallee, Marie...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinre.2021.101709.  , 2021
 
?
5

Three fluoropyrimidine-based regimens in routine clinical p..:

Pointet, Anne-Laure ; Tougeron, David ; Pernot, Simon...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinre.2019.08.009.  , 2020
 
?
6

Three fluoropyrimidine-based regimens in routine clinical p..:

Pointet, Anne-Laure ; Tougeron, David ; Pernot, Simon...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinre.2019.08.009.  , 2020
 
?
7

Three fluoropyrimidine-based regimens in routine clinical p..:

Pointet, Anne-Laure ; Tougeron, David ; Pernot, Simon...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.clinre.2019.08.009.  , 2020
 
?
8

Folfirinox versus gemcitabine/nab-paclitaxel as first-line ..:

Williet, Nicolas ; Saint, Angélique ; Pointet, Anne-Laure...
info:eu-repo/semantics/altIdentifier/doi/10.1177/1756284819878660.  , 2019
 
?
9

Folfirinox versus gemcitabine/nab-paclitaxel as first-line ..:

Williet, Nicolas ; Saint, Angélique ; Pointet, Anne-Laure...
info:eu-repo/semantics/altIdentifier/doi/10.1177/1756284819878660.  , 2019
 
?
10

Folfirinox versus gemcitabine/nab-paclitaxel as first-line ..:

Williet, Nicolas ; Saint, Angélique ; Pointet, Anne-Laure...
info:eu-repo/semantics/altIdentifier/doi/10.1177/1756284819878660.  , 2019
 
?
11

Folfirinox versus gemcitabine/nab-paclitaxel as first-line ..:

Williet, Nicolas ; Saint, Angélique ; Pointet, Anne-Laure...
info:eu-repo/semantics/altIdentifier/doi/10.1177/1756284819878660.  , 2019
 
?
12

Folfirinox versus gemcitabine/nab-paclitaxel as first-line ..:

Williet, Nicolas ; Saint, Angélique ; Pointet, Anne-Laure...
info:eu-repo/semantics/altIdentifier/doi/10.1177/1756284819878660.  , 2019
 
?
13

Folfirinox versus gemcitabine/nab-paclitaxel as first-line ..:

Williet, Nicolas ; Saint, Angélique ; Pointet, Anne-Laure...
info:eu-repo/semantics/altIdentifier/doi/10.1177/1756284819878660.  , 2019
 
?
14

Evaluation of efficacy and efficiency of a pragmatic interv..:

Pozet, Astrid ; Lejeune, Catherine ; Bonnet, Magalie...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s13063-016-1622-8.  , 2016
 
?
15

Evaluation of efficacy and efficiency of a pragmatic interv..:

Pozet, Astrid ; Lejeune, Catherine ; Bonnet, Magalie...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s13063-016-1622-8.  , 2016
 
1-15